Warren Averett Asset Management LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 3.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,052 shares of the company’s stock after buying an additional 488 shares during the quarter. Warren Averett Asset Management LLC’s holdings in Johnson & Johnson were worth $1,826,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. R.M.SINCERBEAUX Capital Management LLC boosted its holdings in shares of Johnson & Johnson by 11.7% during the 2nd quarter. R.M.SINCERBEAUX Capital Management LLC now owns 3,652 shares of the company’s stock valued at $443,000 after acquiring an additional 382 shares during the last quarter. SFE Investment Counsel boosted its holdings in shares of Johnson & Johnson by 1.8% during the 2nd quarter. SFE Investment Counsel now owns 22,110 shares of the company’s stock valued at $2,683,000 after acquiring an additional 383 shares during the last quarter. Capital Advantage Inc. boosted its holdings in shares of Johnson & Johnson by 4.4% during the 2nd quarter. Capital Advantage Inc. now owns 9,436 shares of the company’s stock valued at $1,145,000 after acquiring an additional 394 shares during the last quarter. Gardner Russo & Gardner LLC boosted its holdings in shares of Johnson & Johnson by 30.4% during the 1st quarter. Gardner Russo & Gardner LLC now owns 1,715 shares of the company’s stock valued at $220,000 after acquiring an additional 400 shares during the last quarter. Finally, Diamant Asset Management Inc. boosted its holdings in shares of Johnson & Johnson by 1.3% during the 2nd quarter. Diamant Asset Management Inc. now owns 31,130 shares of the company’s stock valued at $3,777,000 after acquiring an additional 400 shares during the last quarter. 66.06% of the stock is currently owned by hedge funds and other institutional investors.

In other news, CAO Ronald A. Kapusta sold 7,899 shares of the stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $137.18, for a total value of $1,083,584.82. Following the transaction, the chief accounting officer now owns 25,725 shares in the company, valued at approximately $3,528,955.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Ronald A. Kapusta sold 8,441 shares of the stock in a transaction that occurred on Thursday, November 8th. The stock was sold at an average price of $145.15, for a total transaction of $1,225,211.15. Following the completion of the transaction, the chief accounting officer now owns 17,284 shares in the company, valued at approximately $2,508,772.60. The disclosure for this sale can be found here. Insiders sold a total of 349,805 shares of company stock worth $50,593,707 in the last quarter. Company insiders own 0.22% of the company’s stock.

Shares of NYSE:JNJ opened at $146.45 on Wednesday. Johnson & Johnson has a twelve month low of $118.62 and a twelve month high of $148.75. The company has a current ratio of 1.72, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $396.35 billion, a PE ratio of 20.06, a price-to-earnings-growth ratio of 2.31 and a beta of 0.58.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.03 by $0.02. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The firm had revenue of $20.35 billion for the quarter, compared to analysts’ expectations of $20.05 billion. During the same quarter in the prior year, the business earned $1.90 EPS. The business’s quarterly revenue was up 3.6% on a year-over-year basis. As a group, analysts expect that Johnson & Johnson will post 8.16 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Tuesday, November 27th will be paid a $0.90 dividend. This represents a $3.60 annualized dividend and a dividend yield of 2.46%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.

A number of analysts have recently issued reports on JNJ shares. Raymond James raised their price target on shares of Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Credit Suisse Group raised their price target on shares of Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Citigroup raised their price target on shares of Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a report on Monday, October 22nd. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Finally, Wells Fargo & Co reaffirmed an “outperform” rating and set a $160.00 price target (up previously from $155.00) on shares of Johnson & Johnson in a report on Wednesday, October 17th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company. Johnson & Johnson has a consensus rating of “Hold” and an average target price of $143.97.

ILLEGAL ACTIVITY NOTICE: “Warren Averett Asset Management LLC Acquires 488 Shares of Johnson & Johnson (JNJ)” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2018/11/21/warren-averett-asset-management-llc-acquires-488-shares-of-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Calculate Your Return on Investment (ROI)

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.